Vimpat Lacosamide Patient Education
Links shared publicly online about this topic
Vimpat (lacosamide) provided sustained efficacy and good tolerability for up to 8 years in patients with partial onset seizures - Drugs.com MedNews
drugs.com — “Long term data from four open label lacosamide extension trials reported at the 29th International Epilepsy Congress New non-interventional study (VITOBA ) aims” View full resource at drugs.com
Most Recently Shared on September 1, 2011 at 10:01 pm By:
Drugs and Devices OW OW Health
Vimpat (lacosamide) provided sustained efficacy and good tolerability for up to 8 years in patients with p... http://t.co/oazh0jZ #drug
UCB Media Centre - Vimpat® (lacosamide) provided sustained efficacy and good tolerability for up to 8 years in patients with partial onset seizures
ucb.presscentre.com — “For the attention of accredited medical writers only• Long term data from four open label lacosamide extension trials reported at the 29th International Epilepsy Congress • New non-interventional study (VITOBA™) aims to investigate additive or synergistic effects of lacosamide with single antiepileptic drug (AED) treatment” View full resource at ucb.presscentre.com
Most Recently Shared on August 31, 2011 at 12:24 pm By:
Actually the UCB/Vimpat link is this: http://t.co/Sgp6Aff
Oral solution formulation of Vimpat available - ONA
oncologynurseadvisor.com — “UCB announced that it has made available an oral solution formulation of Vimpat (lacosamide), an antiepileptic drug for the add-on treatment of partial-onset seizures in patients 17 years of age with epilepsy.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 14, 2010 at 7:04 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Oral solution formulation of Vimpat available http://goo.gl/fb/ZDGZD
Oral solution formulation of Vimpat available - MPR
empr.com — “UCB announced that it has made available an oral solution formulation of Vimpat (lacosamide), an antiepileptic drug for the add-on treatment of partial-onset seizures in patients 17 years of age with epilepsy.” View full resource at empr.com
Most Recently Shared on June 14, 2010 at 7:12 pm By:
MPR News: Oral solution formulation of Vimpat available: UCB announced that it has made available an oral solution... http://bit.ly/baE9n4
New Oral Solution Formulation Of Antiepileptic Drug Vimpat (Lacosamide) (C-V)
medicalnewstoday.com — “UCB has announced the availability of an oral solution formulation of Vimpat® (lacosamide) C-V, an antiepileptic drug (AED) for add-on treatment of partial-onset seizures in people with epilep” View full resource at medicalnewstoday.com
Most Recently Shared on June 16, 2010 at 12:14 pm By:
MNT Caregivers News Health News
New Oral Solution Formulation Of Antiepileptic Drug Vimpat (Lacosamide) (C-V) http://mnt.to/3DVb #caregivers
Vimpat® (lacosamide) Significantly Reduced Partial-Onset Seizures Regardless Of The Mechanism Of Action Of Concomitant Antiepileptic Drugs
medicalnewstoday.com — “Comprehensive analyses of pooled data from three randomized, double-blind, placebo-controlled Phase II/III trials showing the efficacy and tolerability of Vimpat® (lacosamide) C-V for patients” View full resource at medicalnewstoday.com
Most Recently Shared on January 13, 2011 at 3:05 pm By:
MNT Pharma News Health News and Pharma
Vimpat® (lacosamide) Significantly Reduced Partial-Onset Seizures Regardless Of The Mechanism Of Action Of Concomi... http://mnt.to/3PXs
Long-term Use of Antiepileptic Drug Vimpat (Lacosamide) C-V Effectively Reduced Partial-Onset Seizure Frequency and Improved Health-related Quality of Life - Drugs.com MedNews
drugs.com — “Data presented at the 64th Annual Meeting of the American Epilepsy Society - First presentation of the effects of long-term Vimpat treatment on patients self-re” View full resource at drugs.com
Most Recently Shared on December 7, 2010 at 9:07 pm By:
Drugs and Devices OW OW Health
Long-term Use of Antiepileptic Drug Vimpat (Lacosamide) C-V Effectively Reduced Partial-Onset Seizure Freq... http://bit.ly/gFrSKZ #drug
Vimpat (lacosamide) Significantly Reduced Partial-Onset Seizures Regardless of the Mechanism of Action of Concomitant Antiepileptic Drugs - Drugs.com MedNews
drugs.com — “Comprehensive lacosamide analyses published in CNS Drugs - Pooled phase II III clinical trial data demonstrated efficacy and tolerability of lacosamide as adjun” View full resource at drugs.com
Most Recently Shared on January 12, 2011 at 7:18 pm By:
Drugs and Devices OW OW Health
Vimpat (lacosamide) Significantly Reduced Partial-Onset Seizures Regardless of the Mechanism of Action of ... http://bit.ly/dQh82u #drug
12 New Epilepsy Drugs Usher In "Era Of Abundance"
medicalnewstoday.com — “A dozen new epilepsy drugs are giving doctors and patients more options, but making treatment decisions more complex, a Loyola epilepsy specialist reports in the journal Neurologic Clinics.” View full resource at medicalnewstoday.com
Most Recently Shared on October 22, 2010 at 2:05 pm By:
12 New Epilepsy Drugs Usher In "Era Of Abundance" http://mnt.to/3Lzg #epilepsy
Hospital Pharmacy Europe - UCB commitment to epilepsy community
hospitalpharmacyeurope.com — “Pharmacy Europe, daily news for pharmacists, hundreds of clinical and best practice articles, online comment and video presentations.” View full resource at hospitalpharmacyeurope.com
Most Recently Shared on February 15, 2011 at 1:33 am By:
UCB commitment to epilepsy community: Marking "100,000 patients treated" milestone for Vimpat® (lacosamide) in ... http://bit.ly/fOuWsk
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Drugs and Devices OW
Organizing drug and medical device resources shared by health experts, advocates, and organizations into WisdomCards.
-
FiercePharma
FiercePharma's 140. Join 50,000 pharma insiders on our free newsletter at FiercePharma.com
-
OncologyNurseAdvisor
Oncology Nurse Advisor offers clinical updates and evidence-based guidance to the oncology nurse community and includes regular coverage of a variety of topics.
Advertisement
